Qingdao Haier Biomedical Co Ltd (688139) — Cash Flow-to-Debt Ratio
Qingdao Haier Biomedical Co Ltd (688139) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2023, meaning its operating cash flow of CN¥7.33 Million could theoretically repay 0% of its total liabilities (CN¥1.15 Billion) in one year. See 688139 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Qingdao Haier Biomedical Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Qingdao Haier Biomedical Co Ltd across 10 annual periods. Also explore Qingdao Haier Biomedical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Qingdao Haier Biomedical Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Qingdao Haier Biomedical Co Ltd. For market capitalisation and broader financial context, see Qingdao Haier Biomedical Co Ltd (688139) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | CN¥267.89 Million | CN¥1.17 Billion | ▼ -8.1% |
| 2024 | 0.25x | CN¥291.67 Million | CN¥1.17 Billion | ▲ +8.6% |
| 2023 | 0.23x | CN¥249.26 Million | CN¥1.09 Billion | ▼ -51.3% |
| 2022 | 0.47x | CN¥632.43 Million | CN¥1.34 Billion | ▼ -5.9% |
| 2021 | 0.50x | CN¥632.43 Million | CN¥1.26 Billion | ▼ -16.6% |
| 2020 | 0.60x | CN¥696.62 Million | CN¥1.16 Billion | ▲ +24.6% |
| 2019 | 0.48x | CN¥280.49 Million | CN¥581.08 Million | ▲ +260.9% |
| 2018 | 0.13x | CN¥149.00 Million | CN¥1.11 Billion | ▼ -48.1% |
| 2017 | 0.26x | CN¥148.32 Million | CN¥575.92 Million | ▼ -73.6% |
| 2016 | 0.97x | CN¥220.72 Million | CN¥226.46 Million | — |